Why the study?
Does interleukin-2 reduce parasitemia and myocarditis in mice infected with Trypanosoma cruzi?
Does interleukin-2 reduce parasitemia and myocarditis in mice infected with Trypanosoma cruzi?
In a murine model of Chagas' disease, IL-2 treatment significantly decreased parasitemia and myocardial cell infection, though it had minimal effect on reducing myocardial inflammation.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in Chagas disease; leaves open translation of murine IL-2 effects to human trials.
Previous investigations showed that interleukin-2 (IL-2) administered in vivo into mice infected with Trypanosoma cruzi reduced levels of parasitemia and increased longevity. Present experiments examined the effect of administration of different doses of IL-2 at different times during infection in mice on parasitemia and histopathology of heart tissue. Two different doses of IL-2 (1,500 or 10,000 U) given at 3 different times during infection were equivalent in reducing parasitemia. All of the IL-2 treated groups of mice had significantly lower numbers of circulating trypomastigotes as compared with controls not receiving this lymphokine. This IL-2 treatment of T. cruzi-infected mice resulted also in lower numbers of pseudocysts in all 4 ventricular regions in the hearts. This was particularly evident in the more severely infected right ventricular wall; however, a similar decrease was not as apparent in the less severely infected left ventricular wall. The IL-2 treated, infected mice showed minimal or no effect in reducing inflammation of myocardial cells. However, the mildest inflammation of ventricular wall tended to occur in mice receiving IL-2 treatment either as a low dose (1,500 U) or a high dose (10,000 U) at 5, 7 and 9 days after infection as compared with mice treated later on. It was concluded that IL-2 treatment of infected mice produced a significant decrease in parasitemia and decreased infection of myocardial cells.
No takes yet. Share an insight, caveat, or question.
Hulsebos et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: